Anti-4-1BB antibody-based combination therapy augments antitumor immunity by enhancing CD11c(+)CD8(+) T cells in renal cell carcinoma
ONCOLOGY LETTERS(2022)
摘要
To improve the potential treatment strategies of incurable renal cell carcinoma (RCC), which is highly resistant to chemotherapy and radiotherapy, the present study established a combination therapy with immunostimulatory factor (ISTF) and anti-4-1BB monoclonal antibodies (mAbs) to augment the antitumor response in a murine RCC model. ISTF isolated from Actinobacillus actinomycetemcomitans stimulates macrophages, dendritic cells and B cells to produce IL-6, TNF-alpha, nitric oxide and major histocompatibility complex class II expression. 4-1BB (CD137) is expressed in activated immune cells, including activated T cells, and is a promising target for cancer immunotherapy. The administration of anti-4-1BB mAbs promoted antitumor immunity via enhancing CD11c(+)CD8(+) T cells. The CD11c(+)CD8(+) T cells were characterized by high killing activity and IFN-gamma-producing ability, representing a phenotype of active effector cytotoxic T lymphocytes. The present study showed that combination therapy with ISTF and anti-4-1BB mAbs promoted partial tumor regression with established RCC, but monotherapy with ISTF or anti-4-1BB mAbs did not. These effects were speculated to be caused by the increase in CD11c(+)CD8(+) T cells in the spleen and tumor, and IFN-gamma production. These insights into the effector mechanisms of the combination of ISTF and anti-4-1BB mAbs may be useful for targeting incurable RCC.
更多查看译文
关键词
renal cell carcinoma, 4-1BB, immunostimulating factor, CD11c(+)CD8(+) T cells, IFN-gamma
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要